Pharmacokinetic and pharmacodynamic analysis of (E)-2-ene valproyl derivatives of glycine and valproyl derivatives of nipecotic acid

Biopharmaceutics and Drug Disposition

Volumn 17, Issue 7, 1996, Pages 565-575

  Bialer, Meir ^a   Kadry, Bashier ^a   Abdul Hai, Ali ^a   Haj Yehia, Abdullah ^a   Sterling, Jeff ^b   Herzig, Yaacov ^b   Shirvan, Mitchel ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b Teva Pharmaceutical Industries ^*  (Israel)

Author keywords

(E) 2 ene valproyl glycinamide; Anticonvulsant activity; Structure pharmacokinetic pharmacodynamic relationships (SPPR); Valproyl nipecotamide; Valproyl nipecotic acid

Indexed keywords

4 AMINOBUTYRIC ACID; DRUG METABOLITE; GLYCINE; NIPECOTIC ACID; TIAGABINE; VALPROIC ACID; VALPROIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CONVULSION; DOG; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG STRUCTURE; DRUG URINE LEVEL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; RAT;

ANIMALS; ANTICONVULSANTS; DOGS; DRUG STABILITY; GLYCINE; MICE; NIPECOTIC ACIDS; RATS; SPECIES SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP; VALPROIC ACID;

EID: 0029766213     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199610)17:7<565::AID-BDD979>3.0.CO;2-I     Document Type: Article

References (36)

1. B. S. Meldrum, Epilepsy and gamma-aminobutyric acid-mediated inhibitition. Int. Rev. Neurobiol., 17, 1-36 (1975).
2. E. Roberts, T. N. Chase and D. B. Tower (Eds), GABA in Nervous System Function, Raven, New York, 1976.
3. J. Roba, R. Cavalier, A. Cordi, H. Gorissen, M. Herin, P. Janssens de Varabeke, C. Onkelinx, M. Remacle and W. van Dorsser, Milacemide. In New Anticonvulsant Drugs, B. S. Meldrum and R. J. Porter (Eds), Libby, London, 1986, pp. 179-190.
4. D. M. Lambert, J. H. Poupaert, J-M. Maloteaux and P. Dumont, Anticonvulsant activities of N-Benzyloxycarbonyl glycine after parenteral administration. Neuroreport, 5, 777-780 (1994).
5. J. Liu, N. Seiler, C. Marescaux, A. Depaulis and M. Vergns, Potentiation of γ-vinyl GABA (vigabatrin) effects by glycine. Eur. J. Pharmacol., 182, 109-115 (1990).
6. E. Toth and A. Lajtha, Glycine potentiates the action of some anticonvulsant drugs in some seizure models. Neurochem. Res., 8, 1711-1718 (1984).
7. J. D. Wood, P. Krogsgaard-Larsen and A. Schousboe, Amplification by glycine of the effect of the GABA transport inhibitor THPO on synaptosomal GABA level. Neurochem. Res., 13, 917-921 (1988).
8. N. Seiler and S. Sarhan, Synergistic anticonvulsant effects of a GABA agonist and glycine. Gen. Pharmacol., 15, 367-369 (1984).
9. P. Krogsgaard-Larsen, Inhibitors of the GABA uptake systems. Mol. Cell. Biochem., 31, 105-121 (1980).
10. M. J. Croucher, B. S. Meldrum and P. Krogsgaard-Larsen, Anticonvulsant activity of GABA uptake inhibitors and their prodrugs following central or systemic administration. Eur. J. Pharmacol., 89, 217-228 (1983).
11. L. H. Østergraad, L. Gram and M. Dam, Tiagabine. In Antiepileptic Drugs, 4th edn, R. H. Levy, R. H. Mattson and B. S. Meldrum (Eds), Raven, New York, 1995, pp. 1057-1061.
12. M. W. Pierce, P. D. Suzdak, L. E. Gustavson, H. B. Mengel, J. F. McKelvy and T. Mant, Tiagabine. In New Antiepileptic Drugs (Epilepsy Res. Suppl. 3), F. Pisani, E. Perucca, G. Avanzine and A. Richens (Eds), Elsevier, Amsterdam, 1991, pp. 157-160.
13. P. Krogsgaard-Larsen, H. Hjeds, E. Falach, F. S. Jorgensen and L. Neilsen, Recent advances in GABA agonists, antagonists and uptake inhibitors: structure-activity relationships and therapeutic potential. Adv. Drug Res., 17, 381-456 (1988).
14. R. H. Levy and D. D. Shen, Valproate absorption, distribution and excretion. In Antiepileptic Drugs, 4th edn, R. H. Levy, R. H. Mattson and B. S. Meldrum (Eds), Raven, New York, 1995, pp. 605-620, and other chapters therein.
15. G. Zaccara, A. Messori and F. Moroni, Clinical pharmacokinetics of valproic acid - 1988. Clin. Pharmacokinet., 15, 367-389 (1988).
16. W. Loscher, Pharmacological, toxicological and neurochemical effects of Δ2(E)-valproate in animals. Pharm. Week., 14, 139-144 (1992).
17. 2-(E)-pentanoate (Δ2(E)-valproate) in healthy male volunteers. Pharm. Week., 14, 152-159 (1992).
18. M. Bialer, Clinical pharmacology of valpromide. Clin. Pharmacokinet., 20, 114-122 (1991).
19. S. Hadad and M. Bialer, Pharmacokinetic and pharmacodynamic analysis of N-valproyl derivatives of glycine and GABA with potential antiepileptic activity. Pharm. Res., 12, 905-910 (1995).
20. H. Nau, R.-S. Siegbert and K. Ebley, Valproic acid-induced neural tube defects in mouse and humans: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanism. Pharmacol. Toxicol., 69, 310-321 (1991).
21. H. Nau and G. Hendrickx, Valproic acid teratogenesis. Atlas Sci. Pharmacol., 52-56 (1987).
22. M. Bialer, M. Friedman and J. Dubrovsky, A rapid GLC assay for monitoring valproic acid and valpromide in plasma. J. Pharm. Sci., 73, 991-993 (1984).
23. M. Gibaldi and D. Perrier, Pharmacokinetics, 2nd edn, Dekker, New York, 1982.
24. L. Z. Benet and R. L. Galeazzi, Non-compartmental determination of steady-state volume of distribution. J. Pharm. Sci., 68, 1071-1074 (1979).
25. K. Yamaoka, T. Nakagawa and T. Uno, Statistical moments in pharmacokinetics. J. Pharmacokinet. Biopharm., 6, 547-558 (1978).
26. K. Yamaoka, Methods for Pharmacokinetic Analysis for Personal Computers, 2nd edn, Nanko-D, Tokyo, 1986, pp. 145-175.
27. R. J. Porter, J. J. Cereghino, G. D. Gladding, B. J. Hessie, H. J. Kupferberg, B. Scoville and B. G. White, Antiepileptic Drug Development Program. Clev. Cin. Quat., 51, 293-305 (1984).
28. W. Loscher, Comparative assay of anticonvulsant and toxic potencies of sixteen gabamimetic drugs. Neuropharmacology, 21, 803-810 (1975).
29. A. M. Crider, T. T. Tita, J. D. Wood and C. N. Hinko, Esters of nipecotic acids as potential anticonvulsants. J. Pharm. Sci., 71, 1214-1219 (1982).
30. L. M. Yunger, P. J. Fowler, P. Zarevics and P. E. Setler, Novel inhibitors of gamma-aminobutyric acid (GABA) uptake: anticonvulsant actions in rats and mice. J. Pharmacol. Exp. Ther., 229, 109-115 (1984).
31. E. A. Swinyard, H. S. White, H. H. Wolf and W. E. Bondinell, Anticonvulsant profiles of the potent and orally active GABA uptake inhibitors SK&F 89976-A and SK&F 100330-A and four prototype antiepileptic drugs in mice and rats. Epilesia, 32, 569-577 (1991).
32. E. W. Karbon, S. J. Enna and J. W. Ferkany, Biochemical and behavioral studies following subchronic administration of GABA uptake inhibitors in mice. Neuropharmacology, 30, 1187-1192 (1991).
33. K. E. Andersen, C. Braestrup, F. C. Gronwald, A. S. Jorgensen, E. B. Nielsen, U. Sonnewald, P. O. Sorensen, P. D. Suzdak and L. J. S. Knutsen. The synthesis of novel GABA uptake inhibitors. I. Elucidation of the structure-activity studies leading to the choice of (R)-1-(4,4-bis(3-methyl-2-thienyl)-3-butenyl)-3-piperidinecarboxylic acid (tiagabine) as an anticonvulsant drug candidate. J. Med. Chem., 36, 1716-1725 (1993).
34. M. R. Pavia, S. J. Lobbsteal, D. Nugiel, D. R. Mayhugh, V. E. Gregor, C. P. Taylor, R. D. Schwarz, L. Brahce and M. G. Vartanian, Structure-activity studies on benzhydrol-containing nipecotic acid and guavacine derivatives as potent, orally-active inhibitors of GABA uptake. J. Med. Chem., 35, 4238-4248 (1992).
35. T. G. Murali-Dhar, L. A. Borden, S. Tyagarajan, K. E. Smith, T. A. Brancheck, R. L. Weinshank and C. Gluchowski, Design, synthesis and evaluation of substituted triarylnipecotic acid derivatives as GABA uptake inhibitors: identification of a ligand with moderate affinity and selectivity for the cloned human GABA transporter. J. Med. Chem., 37, 2334-2342 (1994).
36. M. Bialer and A. Rubinstein, A comparative study on the pharmacokinetics of valpromide after intravenous administration in dogs. J. Pharm. Pharmacol., 35, 607-609 (1983).